Status:
UNKNOWN
Treatment of Chronic GVHD of Liver or Lungs by ECP
Lead Sponsor:
Medical University of Vienna
Conditions:
Chronic Graft-Versus Host Disease
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
Chronic graft-versus-host disease (GVHD) is a major complication of allogeneic hematopoietic stem cell transplantation and the leading cause of death more than 2 years after transplantation.During the...
Eligibility Criteria
Inclusion
- Presence of at least one diagnostic clinical sign of chronic GVHD or an appropriate constellation of distinctive signs confirmed by biopsy or other relevant diagnostic tests
- Presence of liver or lung manifestations of chronic GVHD
- Indication for systemic immunosuppressive therapy defined according to NIH consensus
- No prior immunosuppressive therapy for chronic GVHD of the liver or lungs
- Adequate renal, hepatic, pulmonary and cardiac function
- Karnofsky performance score \>- 50%
- Women of childbearing potential must agree to use a reliable method of birth control for the duration of the study
- Signed written informed consent
Exclusion
- \-
Key Trial Info
Start Date :
December 1 2005
Trial Type :
INTERVENTIONAL
End Date :
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT00271869
Start Date
December 1 2005
Last Update
January 4 2006
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Medical University of Vienna, Department of Medicine I, BMT
Vienna, Austria, A-1090